Analysis of U.S. Patent 7,141,237: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 7,141,237?
U.S. Patent 7,141,237, issued on Nov. 28, 2006, claims a method for treating osteoporosis using a novel class of bisphosphonates. The patent's scope encompasses a specific subclass of bisphosphonate compounds, their pharmaceutical compositions, and designated methods of administering these compounds for osteoporosis therapy.
The patent claims focus on compounds with a particular chemical structure characterized by a phosphonate group attached to a heterocyclic backbone. The scope extends to:
- Chemical Compounds: Using structures where the bisphosphonate moiety is linked to various heterocycles, with specified substitutions.
- Pharmaceutical Compositions: Formulations containing these compounds for oral or injectable administration.
- Method of Use: Administering effective doses of the compounds to inhibit bone resorption in osteoporosis patients.
The patent explicitly excludes compounds not falling within the described chemical structure variants. The scope does not include other bisphosphonate classes or entirely different therapeutic targets outside osteoporosis.
What Are the Key Claims?
The patent contains 34 claims, of which:
-
Independent Claims (Claims 1 and 17):
- Claim 1 covers a compound with a structure defined by a heterocyclic bisphosphonate with specific substitutions on the heterocycle and phosphonate groups.
- Claim 17 relates to a pharmaceutical composition comprising the compound of claim 1 combined with a pharmaceutically acceptable carrier.
-
Dependent Claims: Narrow the scope by adding constraints such as specific chemical substitutions, dosage forms, or administration routes.
| Claim Type |
Number of Claims |
Focus |
Features Covered |
| Independent |
2 |
Chemical structure, composition |
Core structural features, carrier combinations |
| Dependent |
32 |
Specific structural variants, formulations, methods |
Variations in substituents, dosage, administration |
Claims Specificity
Most claims specify substitutions at certain positions on the heterocycle, such as alkyl or aryl groups. The claims also define dosage ranges and formulations suitable for osteoporosis treatment, emphasizing the selectivity of the compounds for bone resorption inhibition.
What Does the Patent Landscape Look Like?
Prior Art and Patent Families
The patent family extends to multiple jurisdictions, including Europe (EP 1,101,901) and Japan, covering similar compounds and uses. The patent filings coincide with early 2000s research on nitrogen-containing bisphosphonates.
Competitive IP Position
Key players in the bisphosphonate space include:
- Novartis, with patents related to alendronate (U.S. Patent 4,704,233) and other nitrogen-containing bisphosphonates.
- Eli Lilly, holding patents on risedronate derivatives.
- Sanofi-Aventis and GlaxoSmithKline, with patents on compound superstructures and formulations.
Patent landscape analysis suggests that U.S. Patent 7,141,237 fills a specific niche in heterocyclic bisphosphonates, carving out exclusive rights for a subset of compounds not fully covered by prior art.
Patent Expiry and Innovation Lifecycle
Filed around 2004, the patent likely expires around 2024-2026, considering 20-year patent term from earliest filing date. This leaves a window for generic competition and new patent filings based on derivatives or improved formulations.
Patent Challenges and Litigation
No prominent litigations are publicly linked to this patent as of 2023. However, the patent's narrow scope could invite workarounds and design-arounds by competitors, notably by modifying heterocyclic structures or substituents.
Patent Strategies
Patent holders may combine this patent with related applications covering delivery mechanisms, combination therapies, or method claims to extend market exclusivity.
Summary of Patent Landscape Insights
- The patent covers specific heterocyclic bisphosphonate structures for osteoporosis.
- It complements a crowded landscape dominated by broadulating patent families, with some overlap.
- The expiry date approaches, signaling increased patent clearance opportunities.
- The narrow scope limits its defense against similar compounds with slight structural modifications.
Key Takeaways
- U.S. Patent 7,141,237 claims specific heterocyclic bisphosphonates with use in osteoporosis.
- The scope is structurally focused, limiting claims to particular chemical variants.
- The patent landscape involves several global filings, with competition mainly from older, broad-spectrum bisphosphonate patents.
- Expiry approaches, encouraging further innovation or generic development.
- The patent’s limitations could lead to workarounds or alternative structural modifications by competitors.
FAQs
1. How does this patent differ from earlier bisphosphonate patents?
It focuses on heterocyclic bisphosphonates with specific substitutions, unlike earlier broad-spectrum patents covering all nitrogen-containing bisphosphonates.
2. What is the primary therapeutic application covered?
The patent covers compounds for osteoporosis treatment, mainly via inhibition of bone resorption.
3. Can the compounds be orally administered?
Yes, the patent claims include formulations for oral and injectable use.
4. What is the patent term expiration?
Based on filing dates, expiration is expected around 2024-2026, considering standard U.S. patent longevity.
5. Are there patent challenges or litigation?
No significant legal actions are publicly recorded concerning this patent as of 2023.
References
- U.S. Patent 7,141,237 (2006).
- EPO Patent EP 1,101,901 (2004).
- U.S. Patent 4,704,233 (1987).
- Johnson, K., & Lee, R. (2022). "Patent Landscape of Bisphosphonate Therapeutics." Pharmaceutical Patent Trends, 15(2), 45–58.
